AMYLIN PHARMA (AMLN) |
Consensus Forecast of AMYLIN PHARMA Revenue in Millions  |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
11/07 |
| $781.00 |
$840.11 |
$758.42 |
$763.80 |
$964.68 |
5.4% |
|
| Consensus Forecast of AMYLIN PHARMA EPS |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| ($1.96) |
($1.78) |
($1.59) |
($1.80) |
($1.20) |
($0.95) |
($0.61) |
$0.16 |
|
EPS FORECASTS
|
This section is designed to find errors as the consensus forecast of EPS. The consensus forecasts for the lines in the AMYLIN PHARMA Income Statement are shown and below each consensus forecast is a wiki section to discuss why the consensus forecast of that item may be high or low
|
|
| Consensus Forecasts of Total Revenue |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
12/05 |
| 1. Total Revenue |
$140.5 |
$510.9 |
$781.0 |
$840.2 |
$762.0 |
$754.8 |
$937.8 |
$1,140.9 |
34.9% |
|
| Discussion by Wiki Users | |
| Last edited Fri May 14, 2010 03:08 AM
by SudiptaMukherjee (Zacks Investment Research) |  |
| Consensus Forecasts of Fully Diluted Shares Outstanding |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| Fully Diluted Shares Outstanding |
105.5 |
123.0 |
132.8 |
137.1 |
140.7 |
144.5 |
149.7 |
153.4 |
|
| Consensus Forecasts of GAAP EPS |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| GAAP EPS |
($2.0) |
($1.8) |
($1.6) |
($2.2) |
($1.3) |
($0.9) |
($0.5) |
|
|
| Discussion by Wiki Users | | The company reported a GAAP net loss was $0.27 per share, for 1Q10, versus $0.34 per share, for 1Q09.
| Last edited Fri May 14, 2010 03:08 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Cost of Goods Sold |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 2. Cost of Goods Sold |
$15.8 |
$50.1 |
$65.4 |
$91.6 |
$83.0 |
$86.4 |
$165.0 |
$220.4 |
| Percent of Revenue |
11% |
10% |
8% |
11% |
11% |
11% |
18% |
19% |
| 3. Gross Profit (1-2) |
$124.70 |
$460.80 |
$715.60 |
$748.60 |
$679.00 |
$668.40 |
$772.80 |
$920.50 |
| Percent of Revenue |
89% |
90% |
92% |
89% |
89% |
89% |
82% |
81% |
|
| Discussion by Wiki Users | |
| Last edited Tue Feb 23, 2010 12:21 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Selling, General and Administrative Expense |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 4. Selling, General and Administrative Expense |
$171.5 |
$268.3 |
$375.8 |
$379.0 |
$334.6 |
$320.3 |
$332.5 |
$344.9 |
| Percent of Revenue |
122% |
53% |
48% |
45% |
44% |
42% |
35% |
30% |
|
| Consensus Forecasts of Research and Development |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 5. Research and Development |
$132.1 |
$212.9 |
$267.3 |
$282.0 |
$187.7 |
$175.7 |
$177.5 |
$191.3 |
| Percent of Revenue |
94% |
42% |
34% |
34% |
25% |
23% |
19% |
17% |
|
| Consensus Forecasts of Pre - Tax Income |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 7. Pre - Tax Income |
($206.8) |
($203.8) |
($191.5) |
($224.9) |
($88.5) |
($23.3) |
($9.8) |
$75.8 |
| 8. Tax provisions |
|
|
|
|
|
|
$0.1 |
$9.1 |
| Percent of Revenue |
|
|
|
|
|
|
-1% |
12% |
| 9. Net Income (7-8) |
|
|
|
|
|
|
$0 |
$66.70 |
|
| AMLN (AMYLIN PHARMA) |
$780.00 |
($177.51) |
-36.2% |
|
|
3.0 |
|
Industry Mean |
|
|
-53% |
16% |
14.37 |
408.7 |
12.7 |
| S&P 500 |
|
|
23% |
11% |
13.71
| 1.9 |
|
|
|
|
|
|
|
|
|
IART (INTEGRA LIFESCI) |
$694.00 |
$56.52 |
15.5% |
12% |
14.66 |
1.6 |
10.3 |
QGEN (QIAGEN NV) |
$1,053.00 |
$146.10 |
9.8% |
20% |
23.19 |
4.6 |
15.2 |
TLCR (TALECRIS BIOTHR) |
$1,542.00 |
|
|
15% |
11.27 |
1.3 |
|
CF is operating cash flow plus after-tax interest expense. |
|
| Discussion of Relative Valuation | | No comments yet. Be the first | | |
|
|
| | |
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 06:15:37 CDT by WikiMigrationBot.
|
